https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-09-12 / Front Mol Biosci 2022;9:754100
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-09-12 / Front Mol Biosci 2022;9:7541002022-09-12 00:00:002022-09-12 00:00:003-Dimensional coculture of breast cancer cell lines with adipose tissue-Derived stem cells reveals the efficiency of oncolytic Newcastle disease virus infection labeling technology
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-08-03 / J Control Release 2022 Sep;349:844-875
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-08-03 / J Control Release 2022 Sep;349:844-8752022-08-03 00:00:002022-08-03 00:00:00Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-07-22 / Front Mol Biosci 2022;9:816510
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-07-22 / Front Mol Biosci 2022;9:8165102022-07-22 00:00:002023-03-07 13:25:25Glucose Deprivation Induced by Acarbose and Oncolytic Newcastle Disease Virus Promote Metabolic Oxidative Stress and Cell Death in a Breast Cancer Model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-06-17 / Pharm Res 2022 Aug;39(8):1851-1866
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-06-17 / Pharm Res 2022 Aug;39(8):1851-18662022-06-17 00:00:002022-06-17 00:00:00Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-01-06 / Expert Rev Vaccines 2022 Mar;21(3):337-353
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-01-06 / Expert Rev Vaccines 2022 Mar;21(3):337-3532022-01-06 00:00:002022-01-06 00:00:00Cancer vaccines as a targeted immunotherapy approach for breast cancer: an update of clinical evidence
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-12-23 / Ther Adv Med Oncol 2021;13:17588359211064653
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-12-23 / Ther Adv Med Oncol 2021;13:175883592110646532021-12-23 00:00:002021-12-23 00:00:00Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients: clinical and translational analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-12-16 / Genes Dis 2023 Mar;10(2):430-446
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-12-16 / Genes Dis 2023 Mar;10(2):430-4462021-12-16 00:00:002021-12-16 00:00:00Oncolytic viruses: A novel treatment strategy for breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-12-16 / Front Oncol 2021;11:789078
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-12-16 / Front Oncol 2021;11:7890782021-12-16 00:00:002021-12-16 00:00:00Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-11-29 / Cancers (Basel) 2021 Nov;13(23)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-11-29 / Cancers (Basel) 2021 Nov;13(23)2021-11-29 00:00:002021-11-29 00:00:00The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-08-20 / Front Immunol 2021;12:669965
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-08-20 / Front Immunol 2021;12:6699652021-08-20 00:00:002021-08-20 00:00:00Autologous Dendritic Cells in Combination With Chemotherapy Restore Responsiveness of T Cells in Breast Cancer Patients: A Single-Arm Phase I/II Trial
